MOTIVATION: Exploring the association between drugs and targets is essential for drug discovery and repurposing. Comparing with the traditional methods that regard the exploration as a binary classification task, predicting the drug-target binding affinity can provide more specific information. Many studies work based on the assumption that similar drugs may interact with the same target. These methods constructed a symmetric graph according to the undirected drug similarity or target similarity. Although these similarities can measure the difference between two molecules, it is unable to analyze the inclusion relationship of their substructure. For example, if drug A contains all the substructures of drug B, then in the message-passing mechanism of the graph neural network, drug A should acquire all the properties of drug B, while drug B should only obtain some of the properties of A. RESULTS: To this end, we proposed a structure-inclusive similarity (SIS) which measures the similarity of two drugs by considering the inclusion relationship of their substructures. Based on SIS, we constructed a drug graph and a target graph, respectively, and predicted the binding affinities between drugs and targets by a graph convolutional network-based model. Experimental results show that considering the inclusion relationship of the substructure of two molecules can effectively improve the accuracy of the prediction model. The performance of our SIS-based prediction method outperforms several state-of-the-art methods for drug-target binding affinity prediction. The case studies demonstrate that our model is a practical tool to predict the binding affinity between drugs and targets. AVAILABILITY AND IMPLEMENTATION: Source codes and data are available at https://github.com/HuangStomach/SISDTA.

Exploring drug-protein interactions (DPIs) through computational methods can effectively reduce the workload and the cost of DPI identification. Previous works try to predict DPIs by integrating and analyzing the unique features of drugs and proteins. They cannot adequately analyze the consistency between the drug features and the protein features due to their different semantics. However, the consistency of their features, such as the correlation originating from their sharing diseases, may reveal some potential DPIs. Here we propose a deep neural network-based co-coding method (DNNCC for short) to predict novel DPIs. DNNCC projects the original features of drugs and proteins to a common embedding space through a co-coding strategy. In this way, the embedding features of drugs and proteins have the same semantics. Therefore, the prediction module can discover the unknown DPIs by exploring the feature consistency between drugs and proteins. The experimental results indicate that the performance of DNNCC is significantly superior to five state-of-the-art DPI prediction methods under several evaluation metrics. The superiority of integrating and analyzing the common features of drugs and proteins is proved by the ablation experiments. The novel DPIs predicted by DNNCC verify that DNNCC is a powerful prior tool that can effectively discover potential DPIs.

Many powerful computational methods based on graph neural networks (GNNs) have been proposed to predict drug-protein interactions (DPIs). It can effectively reduce laboratory workload and the cost of drug discovery and drug repurposing. However, many clinical functions of drugs and proteins are unknown due to their unobserved indications. Therefore, it is difficult to establish a reliable drug-protein heterogeneous network that can describe the relationships between drugs and proteins based on the available information. To solve this problem, we propose a DPI prediction method that can self-adaptively adjust the topological structure of the heterogeneous networks, and name it SATS. SATS establishes a representation learning module based on graph attention network to carry out the drug-protein heterogeneous network. It can self-adaptively learn the relationships among the nodes based on their attributes and adjust the topological structure of the network according to the training loss of the model. Finally, SATS predicts the interaction propensity between drugs and proteins based on their embeddings. The experimental results show that SATS can effectively improve the topological structure of the network. The performance of SATS outperforms several state-of-the-art DPI prediction methods under various evaluation metrics. These prove that SATS is useful to deal with incomplete data and unreliable networks. The case studies on the top section of the prediction results further demonstrate that SATS is powerful for discovering novel DPIs.

MOTIVATION: Effective computational methods to predict drug-protein interactions (DPIs) are vital for drug discovery in reducing the time and cost of drug development. Recent DPI prediction methods mainly exploit graph data composed of multiple kinds of connections among drugs and proteins. Each node in the graph usually has topological structures with multiple scales formed by its first-order neighbors and multi-order neighbors. However, most of the previous methods do not consider the topological structures of multi-order neighbors. In addition, deep integration of the multi-modality similarities of drugs and proteins is also a challenging task. RESULTS: We propose a model called ALDPI to adaptively learn the multi-scale topologies and multi-modality similarities with various significance levels. We first construct a drug-protein heterogeneous graph, which is composed of the interactions and the similarities with multiple modalities among drugs and proteins. An adaptive graph learning module is then designed to learn important kinds of connections in heterogeneous graph and generate new topology graphs. A module based on graph convolutional autoencoders is established to learn multiple representations, which imply the node attributes and multiple-scale topologies composed of one-order and multi-order neighbors, respectively. We also design an attention mechanism at neighbor topology level to distinguish the importance of these representations. Finally, since each similarity modality has its specific features, we construct a multi-layer convolutional neural network-based module to learn and fuse multi-modality features to obtain the attribute representation of each drug-protein node pair. Comprehensive experimental results show ALDPI's superior performance over six state-of-the-art methods. The results of recall rates of top-ranked candidates and case studies on five drugs further demonstrate the ability of ALDPI to discover potential drug-related protein candidates. CONTACT: [email protected].

MOTIVATION: Large-scale heterogeneous data provide diverse perspectives for predicting drug-protein interactions (DPIs). However, the available information on molecular interactions and clinical associations related to drugs or proteins is incomplete because there may be unproven interactions and associations. This incomplete information in the available data is presented in the form of non-interaction and non-correlation, which may mislead the prediction model. Existing methods fuse incomplete and complete information without considering their integrity, so the negative effects of incomplete information still exist. RESULTS: We develop a network-based DPI prediction method named BRWCP, which uses the complete information network to correct the prediction results acquired by the incomplete information network. By integrating relevant heterogeneous information that may be incomplete, the feature similarities of drugs and proteins are obtained. Combining the feature similarities and known DPIs, an incomplete information-based drug-protein heterogeneous network is constructed. Then, a bidirectional random walk with pruning algorithm is adopted in this heterogeneous network to predict potential DPIs. Next, the predicted DPIs are combined with the chemical fingerprint similarity of drugs and amino acid sequence similarity of proteins to construct the complete information network. The bidirectional random walk with pruning algorithm is applied in the new network to obtain the final prediction results until it converges. Experimental results show that BRWCP is superior to several state-of-the-art DPI prediction methods, and case studies further confirm its ability to tap potential DPIs. AVAILABILITY AND IMPLEMENTATION: The code and data used in BRWCP are available at https://github.com/lyfdomain/BRWCP. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.

The computational prediction of novel drug-target interactions (DTIs) may effectively speed up the process of drug repositioning and reduce its costs. Most previous methods integrated multiple kinds of connections about drugs and targets by constructing shallow prediction models. These methods failed to deeply learn the low-dimension feature vectors for drugs and targets and ignored the distribution of these feature vectors. We proposed a graph convolutional autoencoder and generative adversarial network (GAN)-based method, GANDTI, to predict DTIs. We constructed a drug-target heterogeneous network to integrate various connections related to drugs and targets, i.e., the similarities and interactions between drugs or between targets and the interactions between drugs and targets. A graph convolutional autoencoder was established to learn the network embeddings of the drug and target nodes in a low-dimensional feature space, and the autoencoder deeply integrated different kinds of connections within the network. A GAN was introduced to regularize the feature vectors of nodes into a Gaussian distribution. Severe class imbalance exists between known and unknown DTIs. Thus, we constructed a classifier based on an ensemble learning model, LightGBM, to estimate the interaction propensities of drugs and targets. This classifier completely exploited all unknown DTIs and counteracted the negative effect of class imbalance. The experimental results indicated that GANDTI outperforms several state-of-the-art methods for DTI prediction. Additionally, case studies of five drugs demonstrated the ability of GANDTI to discover the potential targets for drugs.

MOTIVATION: Exploring the potential drug-target interactions (DTIs) is a key step in drug discovery and repurposing. In recent years, predicting the probable DTIs through computational methods has gradually become a research hot spot. However, most of the previous studies failed to judiciously take into account the consistency between the chemical properties of drug and its functions. The changes of these relationships may lead to a severely negative effect on the prediction of DTIs. RESULTS: We propose an autoencoder-based method, AEFS, under spatial consistency constraints to predict DTIs. A heterogeneous network is established to integrate the information of drugs, proteins and diseases. The original drug features are projected to an embedding (protein) space by a multi-layer encoder, and further projected into label (disease) space by a decoder. In this process, the clinical information of drugs is introduced to assist the DTI prediction. By maintaining the distribution of drug correlation in the original feature, embedding and label space, AEFS keeps the consistency between chemical properties and functions of drugs. Experimental comparisons indicate that AEFS is more robust for imbalanced data and of significantly superior performance in DTI prediction. Case studies further confirm its ability to mine the latent DTIs. AVAILABILITY AND IMPLEMENTATION: The code of AEFS is available at https://github.com/JackieSun818/AEFS. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.